Search Filters

Search Results

Found 2 results

510(k) Data Aggregation

    K Number
    K182600
    Date Cleared
    2018-11-30

    (70 days)

    Product Code
    Regulation Number
    880.6250
    Reference & Predicate Devices
    Why did this record match?
    Device Name :

    Powder Free Nitrile Examination Glove, Tested for Use with Chemotherapy Drugs (Blue)

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Powder Free Nitrile Examination Gloves, Tested for Use with Chemotherapy Drugs (Blue) is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner. Gloves have been tested for use with chemotherapy drugs using ASTM D6978 and will be labeled with a statement of compliance and a summary of the testing results.

    Device Description

    Powder Free Nitrile Examination Gloves, Tested for Use with Chemotherapy Drugs (Blue) are Class I Patient Examination Gloves and Specialty Chemotherapy Gloves. They are ambidextrous and come in different sizes-Extra Small, Medium, Large and Extra Large. Gloves meet the specification of ASTM D6319-10(2015) and have been tested for resistance to permeation by chemotherapy drugs as per ASTM D6978-05(2013).

    AI/ML Overview

    This document is a 510(k) summary for the "Powder Free Nitrile Examination Gloves, Tested for Use with Chemotherapy Drugs (Blue)". It describes the device, its intended use, and comparative testing against a predicate device.

    Here's the breakdown of the acceptance criteria and study information:

    1. Table of Acceptance Criteria and Reported Device Performance

    The device performance is primarily evaluated against two standards: ASTM D6319-10(2015) for Nitrile Examination Gloves (General Characteristics) and ASTM D6978-05(2013) for Chemotherapy Drug Permeation. Specific acceptance criteria are not explicitly stated for all parameters, but rather the performance of the proposed device is compared to the predicate device and relevant ASTM standards.

    The table below summarizes the key performance characteristics and reported results. For characteristics not explicitly having acceptance criteria listed as a specific number, the "Comparison" column indicates if the device is "Same" or "Similar" to the predicate, implying it meets comparable performance.

    Test Parameter / Acceptance Criteria (as per ASTM standards or comparison)Reported Device Performance (Proposed Device K182600)
    General Characteristics (ASTM D6319-10(2015))
    LengthMinimum 230mm
    Palm Width (XS)$70\pm10$ mm
    Palm Width (S)$80\pm10$ mm
    Palm Width (M)$95\pm10$ mm
    Palm Width (L)$110\pm10$ mm
    Palm Width (XL)$120\pm10$ mm
    Thickness (Finger)Minimum 0.05 mm
    Thickness (Palm)Minimum 0.05 mm
    Tensile Strength, Before Aging14MPa, min
    Ultimate Elongation, Before Aging500%, min
    Tensile Strength, After Accelerated Aging14MPa, min
    Ultimate Elongation, After Accelerated Aging400%, min
    Freedom from holes (ASTM D 5151-06, AQL 2.5)In accordance with ASTM D 5151-06, following ASTM D6319-10, G-1, AQL 2.5
    Powder-Content$\le2$ mg per glove
    Biocompatibility (ISO 10993)
    ISO 10993-10:2010 Skin Irritation StudyNot an irritant
    ISO 10993-10:2010 Maximization Sensitization StudyNot a sensitizer
    ISO 10993-5:2009 Cytotoxicity TestNot a cytotoxic potential
    Chemotherapy Drug Permeation (ASTM D6978-05(2013))Minimum Breakthrough Detection Time (Minutes)
    Carmustine(BCNU) (3.3 mg/ml)11.0
    Cisplatin (1mg/ml)>240
    Cyclophosphamide (20mg/ml)>240
    Dacarbazine (DTIC) (10mg/ml)>240
    Doxorubicin Hydrochloride (2mg/ml)>240
    Etoposide (Toposar) (20mg/ml)>240
    Fluorouracil (50mg/ml)>240
    Methotrexate (25mg/ml)>240
    Paclitaxel (Taxol) (6mg/ml)>240
    Thiotepa (THT) (10mg/ml)28.8
    Bleomycin (15.0mg/ml)>240
    Busulfan (6.0mg/ml)>240
    Carboplatin, (10.0mg/ml)>240
    Chloroquine, (50.0mg/ml)>240
    Cyclosporin, (100.0mg/ml)>240
    Cytarabine, (100.0mg/ml)>240
    Daunorubicin, (5.0mg/ml)>240
    Docetaxel, (10.0mg/ml)>240
    Epirubicin (Ellence), (2.0mg/ml)>240
    Fludarabine, (25.0mg/ml)>240
    Gemcitabine (Gemzar) (38.0mg/ml)>240
    Idarubicin, (1.0mg/ml)>240
    Ifosfamide, (50.0mg/ml)>240
    Irinotecan, (20.0mg/ml)>240
    Mechlorethamine HCI, (1.0mg/ml)>240
    Melphalan, (5.0mg/ml)>240
    Mitomycin C, (0.5mg/ml)>240
    Mitoxantrone, (2.0mg/ml)>240
    Oxaliplatin, (2.0mg/ml)>240
    Paraplatin, (10.0mg/ml)>240
    Retrovir, (10.0mg/ml)>240
    Rituximab, (10.0mg/ml)>240
    Topotecan HCL, (1.0mg/ml)>240
    Trisonex, (1.0mg/ml)>240
    Velcade (Bortezomib), (1.0mg/ml)>240
    Vincristine, (1.0mg/ml)>240

    2. Sample size used for the test set and the data provenance

    The document does not specify the exact sample sizes (number of gloves or test replicates) used for each individual test (e.g., tensile strength, freedom from holes, chemotherapy permeation). It references the ASTM standards, which typically define the appropriate sample sizes and testing methodologies.

    The data provenance is from non-clinical testing conducted by Better Care Plastic Technology Co., Ltd. located in Hebei Province, China. The data is prospective in the sense that these tests were conducted specifically to support this 510(k) submission.

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

    This information is not applicable as the evaluation of these medical gloves relies on objective measurements performed according to recognized international standards (ASTM, ISO). There is no "ground truth" derived from expert consensus on medical images or clinical outcomes for this type of device. The "truth" is established by the standardized test methods themselves and the resulting physical and chemical measurements.

    4. Adjudication method for the test set

    This information is not applicable. The tests performed are objective, quantitative measurements according to predefined standards. There is no subjective assessment requiring adjudication.

    5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    This information is not applicable. This is a medical glove, a physical device, and not an AI-powered diagnostic or assistive technology for human readers.

    6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done

    This information is not applicable. As mentioned above, this is a physical medical device, not an algorithm or AI system.

    7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

    The "ground truth" for the performance of these gloves is based on objective measurements derived from standardized test methods (ASTM D6319-10, ASTM D6978-05, ISO 10993 series). For example:

    • Physical properties (e.g., tensile strength, elongation): Measured directly by testing equipment following ASTM protocols.
    • Freedom from holes: Determined by a standardized water-leak test (ASTM D5151-06).
    • Chemotherapy drug permeation: Measured by detecting the breakthrough of chemotherapy drugs through the glove material over time, as per ASTM D6978-05.
    • Biocompatibility: Evaluated using established in-vitro and in-vivo biological tests (cytotoxicity, irritation, sensitization) according to ISO 10993 standards.

    8. The sample size for the training set

    This information is not applicable. There is no "training set" in the context of validating a medical glove. The product is manufactured and then tested to ensure it meets performance standards.

    9. How the ground truth for the training set was established

    This information is not applicable for the reasons stated in point 8.

    Ask a Question

    Ask a specific question about this device

    K Number
    K140816
    Date Cleared
    2014-07-08

    (98 days)

    Product Code
    Regulation Number
    880.6250
    Reference & Predicate Devices
    Why did this record match?
    Device Name :

    POWDER FREE NITRILE EXAMINATION GLOVE, TESTED FOR USE WITH CHEMOTHERAPY DRUGS (BLUE)

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    A patient examination glove is disposable non-sterile device intended for medical purpose that is worn on the examiner's hand or finger to prevent contamination between patient and examiner.

    The tested chemotherapy drugs and their breakthrough detection times are as follows:

    Test Chemotherapy Drug and ConcentrationAverage BDT
    Fluorouracil, 50.0mg/ml (50,000ppm)>240 min.
    Etoposide (Toposar), 20.0mg/ml (20,000ppm)>240 min.
    Cyclophosphamide (Cytoxan), 20mg/ml (20,000ppm)>240 min.
    Carmustine (BCNU), 3.3mg/ml (3,300ppm)2.3 min.
    Thiotepa, 10.0mg/ml (10,000ppm)30.9 min.
    Paclitaxel (Taxol), 6.0mg/ml (6,000ppm)>240 min.
    Doxorubicin Hydrochloride, 2.0mg/ml (2,000ppm)>240 min.
    Dacarbazine (DTIC), 10.0mg/ml (10,000ppm)>240 min.
    Cisplatin, 1.0mg/ml (1,000ppm)>240 min.

    Please note that Carmustine and Thiotepa have extremely low permeation times of 30.9 minutes and 2.3 minutes, respectively.

    Device Description

    Powder Free Nitrile Examination Glove, Tested for Use with Chemotherapy Drugs (Blue) are Patient Examination Gloves, Disposable, single use only and non-sterile. The gloves are made of nitrile rubber materials and are powder free. The physical and performance characteristics of the devices meet all requirements of ASTM standard D 6319-10 Standard Specification for Nitrile Examination Gloves for Medical Application.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and the study information for the Powder Free Nitrile Examination Glove, Tested for Use with Chemotherapy Drugs (Blue), based on the provided text:

    1. Table of Acceptance Criteria and Reported Device Performance

    CharacteristicStandard/Acceptance CriteriaReported Device Performance
    Product CodeLZALZA
    Intended UseDisposable non-sterile device for medical purposes, worn on hand/finger to prevent contamination.Meets
    Chemotherapy Drugs (Breakthrough Detection Time - BDT)Fluorouracil, Etoposide, Cyclophosphamide, Paclitaxel, Doxorubicin HCl, Dacarbazine, Cisplatin: >240 minFluorouracil (50.0mg/ml): >240 min
    Etoposide (20.0mg/ml): >240 min
    Cyclophosphamide (20mg/ml): >240 min
    Paclitaxel (6.0mg/ml): >240 min
    Doxorubicin HCl (2.0mg/ml): >240 min
    Dacarbazine (10.0mg/ml): >240 min
    Cisplatin (1.0mg/ml): >240 min
    Carmustine & Thiotepa: Permeation times should be reported.Carmustine (3.3mg/ml): 2.3 min
    Thiotepa (10.0mg/ml): 30.9 min
    LabelingNo special labeling claims, no hypoallergenic claims.Meets
    Device MaterialsNitrile compoundNitrile Compound
    ColorBlueBlue
    Tensile strength (before/after aging)ASTM D6319-10 (Meets)Meets
    Ultimate elongation (before/after aging)ASTM D6319-10 (Meets)Meets
    Freedom from pinholesASTM D6319-10, ASTM D5151-06 (2011), 21CFR800.20 (Meets)Meets
    Dimensions (Overall length, Width, Palm, Finger thickness)ASTM D6319-10 (Meets)Meets
    Residual powderASTM D6319-10, ASTM D6124 (Meets)Meets
    Primary skin irritation testISO 10993-10 (Not an irritant)Not an irritant
    Dermal sensitization assayISO 10993-10 (Not a sensitizer)Not a sensitizer
    Resistance to PermeationASTM D6978-05 (Specific breakthrough times for chemotherapy drugs)Carmustine: 2.3 minutes
    Thiotepa: 30.9 minutes
    Other specified drugs: >240 minutes

    2. Sample Size Used for the Test Set and Data Provenance

    The document does not explicitly state the sample sizes used for the individual tests (e.g., tensile strength, pinholes, biocompatibility, resistance to permeation). However, it indicates that the device's physical and performance characteristics meet the requirements of ASTM D 6319-10 and ASTM D 6978-05, which are standards that specify testing methodologies and, implicitly, sample sizes (e.g., AQL levels for pinholes).

    The data provenance is from non-clinical tests performed to demonstrate substantial equivalence to a predicate device. The country of origin for the device manufacturer is CHINA (Hebei Province). The testing itself (e.g., ASTM standards, ISO standards) is generally applicable internationally. The document does not specify if the data is retrospective or prospective, but given it's part of a 510(k) submission, it would be considered prospective in the sense that the device was specifically tested to demonstrate compliance for this submission.

    3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications

    This information is not applicable to this type of device and study. The "ground truth" for glove performance is established by standardized testing protocols (e.g., ASTM, ISO) that yield quantitative measurements (e.g., tensile strength values, breakthrough detection times, pass/fail for pinholes, irritation/sensitization ratings). There isn't a need for expert consensus in the way there would be for image interpretation or disease diagnosis.

    4. Adjudication Method for the Test Set

    This is not applicable. As mentioned above, the acceptance criteria are based on objective measurements against established standards, not on subjective interpretations requiring adjudication.

    5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was Done

    No, an MRMC comparative effectiveness study was not conducted. This type of study is relevant for diagnostic devices where human readers (e.g., radiologists) interpret results, and the study aims to assess the impact of an AI tool on their performance. For a medical glove, performance is evaluated through physical, chemical, and biological testing as outlined above.

    6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was Done

    This is not applicable. The device is a physical product (a glove), not an algorithm or AI system. Its performance is inherent to the product itself, not an independent algorithmic output.

    7. The Type of Ground Truth Used

    The ground truth used for this device is based on:

    • Standardized Test Results: Compliance with established industry standards such as ASTM D6319-10 (for physical properties like tensile strength, elongation, dimensions, freedom from holes, residual powder) and ISO 10993-10 (for biocompatibility).
    • Quantitative Measurement: For chemotherapy drug permeation, the "ground truth" is the measured breakthrough detection time (BDT), determined according to ASTM D6978-05.

    8. The Sample Size for the Training Set

    This is not applicable. The device is a physical product, not a machine learning model. Therefore, there is no "training set" in the context of AI/ML. The manufacturing process of the glove and its materials are designed to meet the specifications, and the testing ensures these specifications are met for production batches.

    9. How the Ground Truth for the Training Set was Established

    This is not applicable for the same reasons as #8.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1